Product pipeline

• + Acromegaly - Octreotide
• + Prostate cancer - PCK3145
• + Prostate cancer - Goserelin
• + Cancer - NGR-Delivery Technology
• + HIV/AIDS - Protease Inhibitors
• + HIV/AIDS - Integrase Inhibitors
• + HIV/AIDS - Entry Inhibitors
• + HCV - Polymerase Inhibitors
• + HCV - Entry Inhibitors
• + Influenza A - M2 Proton Channel Inhibitors
• + Diagnostic - PSP94
• + Diagnostic - Colopath® / ColorectAlert™
• + Scientific library

Acromegaly - Octreotide (C2L)

Acromegaly is a rare and serious condition related to the
hypersecretion of growth hormone by the pituitary gland,
generally of tumoral origin. This causes an uncontrolled growth of organs, debilitating symptoms and a shorter life expectancy.

Pharmacotherapy with somatostatin analogs is one of the treatment options, a life-long treatment with a few and mild side effects. Novartis’ Sandostatin® (octreotide) is the market leader with reported 2007 worldwide sales of $US1.0B (+7% y-y growth). Its efficacy is clearly established for treating acromegaly. The yearly treatment with the long-acting release (LAR) formulation of the product, which consists of intramuscular injections every 4 weeks, is costly. Difficult reconstitution prior to injection is also an issue.

Ambrilia has developed an improved, proprietary prolonged release formulation of Octreotide (C2L), easier to reconstitute and which could be the first therapeutic alternative to the long-acting formulation of the original product.

Clinical developement

Phase III clinical studies in acromegaly patients are currently ongoing.